Sugavive M0.5

Product Description

Sugavive M0.5 is designed for the gentle initiation of combination therapy in adults with type 2 diabetes mellitus. This specific formulation is notable for its "micro-dose" of the sulfonylurea component, making it an ideal starting point for patients who require dual therapy but are highly sensitive to sudden drops in blood sugar. Glimepiride (0.5mg): A sulfonylurea at an ultra-low starting dose. It works by stimulating the beta cells of the pancreas to release more insulin. The 0.5mg dose provides a mild, controlled boost in insulin secretion, significantly minimizing the risk of hypoglycemia. Metformin SR (500mg): A biguanide in a Sustained Release formulation. It acts as the foundational therapy by decreasing glucose production in the liver and improving the body's sensitivity to its own insulin. The SR format releases the medication slowly over time, preventing gastrointestinal side effects like nausea and diarrhea. Key Clinical Benefits Maximum Safety Profile: The ultra-low 0.5mg dose of Glimepiride makes this combination highly suitable for elderly patients, those with mild renal impairment, or patients with an unpredictable eating schedule who are at high risk for hypoglycemia. Gentle Titration: It allows physicians to safely introduce a sulfonylurea to a patient's regimen alongside Metformin, with room to step up the dose later if required. Excellent Tolerability: The Sustained Release delivery of Metformin ensures better patient adherence by minimizing stomach upset.

Ingredients